Helmy M Guirgis, MD

Research Reports

Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration, and Immune Checkpoint Inhibitor Combinations

06/18/2019

Helmy M Guirgis, MD

Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-small cell lung cancer (amNSCLC). There is an unmet need...

...

06/18/2019

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

September 18 ⁠–⁠ September 20

September 20 ⁠–⁠ September 22

September 21 ⁠–⁠ September 22

September 30 ⁠–⁠ October 2

October 1 ⁠–⁠ October 2

October 2 ⁠–⁠ October 5

October 5 ⁠–⁠ October 6

October 14 ⁠–⁠ October 16

October 16 ⁠–⁠ October 19

October 19 ⁠–⁠ October 20

See Full Calendar

Helmy M Guirgis, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products